Clinical Trials & Research Studies
Breast cancer clinical trials, also called clinical studies, are a type of research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis or treatment.
In this section, get basic information about breast cancer clinical trials for women who are newly diagnosed, explore whether taking part in a clinical trial is right for you and find studies you may be eligible to participate in.
You can also get information and updates on other breast cancer research studies that follow participants over time to determine treatment outcomes.
The new SystHERs (Systematic Therapies for HER2 positive Metastatic Breast Cancer Study) Registry seeks to enroll 1,000 people with HER2 positive metastatic breast cancer to analyze treatment patterns and outcomes.
Researchers seek 4,000 participants for a clinical trial that will study whether hormonal therapy alone is adequate treatment for early-stage invasive breast cancer that traveled to one to three axillary lymph nodes and is found to be of low or intermediate risk for recurrence by genomic tests.
Premenopausal women who are newly diagnosed with breast cancer and have not yet had chemotherapy are needed to participate in a study looking at biological factors that may relate to ovarian insufficiency after chemotherapy.
If you are affected by early-stage breast cancer that has been indicated to have a high risk of recurrence, find out whether you are eligible to participate in the D-CARE clinical trial, which is considering the impact of denosumab as an adjuvant treatment for Stage II and Stage III breast cancer.
Researchers seek women newly diagnosed with stage I-III breast cancer planning to undergo axillary lymph node dissection for a study on preventing and treating lymphedema.
If you are newly diagnosed, find out whether you are eligible to participate in I-SPY2, a trial measuring the effectiveness of adding new medicines to standard chemotherapy given before surgery.
Phase III trial will compare lapatinib and trastuzumab in preventing recurrence of early-stage, HER2 positive breast cancer after surgery and chemotherapy.